P

Precision Cancer Centers | Ashland-Bellefonte Cancer Center

Research site

(Unclaimed)

Location

122 Street Christopher Drive, Ashland, Kentucky, United States of America

Site insights

Top conditions

Top treatments

Estrogen

Neratinib

Docetaxel

Luspatercept

Injectafer

Palonosetron

Pembrolizumab

-Clivatuzumab

Pegfilgrastim

Debio 1143

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 13 total trials

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of en...

Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Drug: Fulvestrant or an Aromatase Inhibitor (Physician Choice)

Drug: LHRH Agonist

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in...

Active, not recruiting

Squamous Cell Carcinoma of the Head and Neck

Drug: Placebo

Drug: Xevinapant (Debio 1143)